A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
A phase 3 trial testing Abexinostat in renal cell carcinoma, now recruiting.
Overview
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) is a phase 3 interventional study registered as NCT03592472, led by Xynomic Pharmaceuticals, and recruiting when checked on 2026-09-11. Official title: A Randomised, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV). Planned enrolment is 413 participants (estimated). The study started in 2018-07-17 and primary completion is expected in 2026-12-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Shares Renal cell carcinoma and the tag ctgov-ingest.
- TrialA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Shares Renal cell carcinoma and the tag ctgov-ingest.
- TrialA Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Shares Renal cell carcinoma and the tag ctgov-ingest.
- TreatmentADI-270
Shares Renal cell carcinoma and the tag ctgov-ingest.
- TreatmentAL8326
Shares Renal cell carcinoma and the tag ctgov-ingest.
- TreatmentIBI363
Shares Renal cell carcinoma and the tag ctgov-ingest.
- TreatmentTQB2450
Shares Renal cell carcinoma and the tag ctgov-ingest.
- TreatmentJK08
Shares Renal cell carcinoma and the tag ctgov-ingest.